Gossamer Bio (GOSS) plans to raise $230 million in an initial public offering (IPO) on Wednesday, February 13th, IPO Scoop reports. The company will issue 14,400,000 shares at a price of $16.00 per share.
Gossamer Bio has a market-cap of $966.4 million.
BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.
Gossamer Bio provided the following description of their company for its IPO: “(Note: Gossamer Bio has included in the registration statement the proposed public offering price and the number of shares offered and specific language under Rule 473(b) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), such that the registration statement is expected to become automatically effective 20 calendar days after today’s filing, or February 12, 2019, pursuant to Section 8(a) of the Securities Act. Gossamer Bio expects to complete the pricing of the offering on such date. In the event that the federal government and the SEC resume normal operations prior to February 12, 2019, Gossamer Bio will re-evaluate the use of Section 8(a) in connection with the offering. ) We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. “.
Gossamer Bio was founded in 2015 and has 105 employees. The company is located at 3013 Science Park Road, Suite 200, San Diego, CA 92121, US and can be reached via phone at (858) 684-1300 or on the web at http://www.gossamerbio.com.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.